Abstract
Modelling complex disorders presents considerable challenges, and multiple sclerosis (MS) is no exception to this rule. The aetiology of MS is unknown, and its pathophysiology is poorly understood. Moreover, the last two decades have witnessed a dramatic revision of the long-held view of MS as an inflammatory demyelinating white matter disease. Instead, it is now regarded as a global central nervous system (CNS) disorder with a neurodegenerative component. Currently, there is no animal model recapitulating MS immunopathogenesis. Available models are based on autoimmune-mediated demyelination, denoted experimental autoimmune encephalomyelitis (EAE ) or virally or chemically induced demyelination. Of these, the EAE model has been the most commonly used. It has been extensively improved since its first description and now exists as a number of variants, including genetically modified and humanized versions. Nonetheless, EAE is a distinct disease, and each variant models only certain facets of MS. Whilst the search for more refined MS models must continue, it is important to further explore where mechanisms underlying EAE provide proof-of-principle for those driving MS pathogenesis. EAE variants generated with the myelin component myelin oligodendrocyte glycoprotein (MOG ) have emerged as the preferred ones, because in this particular variant disease is associated with both T- and B-cell effector mechanisms, together with demyelination. MOG-induced EAE in the non-obese diabetic (NOD) mouse strain exhibits a chronic-relapsing EAE clinical profile and high disease incidence. We describe the generation of this variant, its contribution to the understanding of MS immune and pathogenetic mechanisms and potential for evaluation of candidate therapies.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdul-Majid K-B, Jirholt J, Stadelmann C, Stefferl A, Kjellen P, Wallstrom E, Holmdahl R, Lassmann H, Olsson T, Harris RA (2000) Screening of several H-2 congenic mouse strains identified H-2q mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J Neuroimmunol 111:23–33
Amiguet P, Gardinier MV, Zanetta J-P, Matthieu J-M (1992) Purification and partial structural and functional characterization of mouse myelin oligodendrocyte glycoprotein. J Neurochem 58:1676–1682
Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier M, Matthieu J-M, Baker D (1994) Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental autoimmune encephalomyelitis in SJL/J and Biozzi AB/H mice. J Immunol 153:4349–4356
Anderson AC, Chandwaksar R, Lee DH, Sullivan JM, Solomon A, Rodriguez-Manzanet R, Greve B, Sobel RA, Kuchroo VK (2012) A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ Tcells. J Immunol 188(5):2084–2092
Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME (2005) NOD mice and autoimmunity. Autoimmun Rev 4:373–379
Arai H, Munoz JJ (1981) Crystallization of pertussisgen from Bordetella pertussis. Infect Immun 31:495–499
Ayers MM, Hazelwood LJ, Catmull DV, Wang D, McKormack Q, Bernard C, Orian JM (2004) Early glial responses in murine models of multiple sclerosis. Neurochem Int 45:409–419
Baker D, Gerritsen W, Rundle J, Amor S (2011) Critical appraisal of animal models of multiple sclerosis. Mult Scler J 17(6):647–657
Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovi S, Puckett L, Monsonegro A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse mocel of progressive multiple sclerosis. J Clin Invest 118(4):1532–1543
Baxter AG (2007) The origins and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7:904–912
Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11(3):195–199
Ben-Nun A, Kaushansky N, Kawakami N, Krishnamoorthy G, Berer K, Liblau R, Hohlfeld R, Wekerle H (2014) From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J Autoimmun 54:33–50
Berard JL, Wolak K, Fournier S, David S (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C58Bl/6 mice. Glia 58:434–445
Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145
Bergman R, Munoz J, Portis J (1978) Vascular permeability changes in the central nervous system of rats with hyperacute experimental allergic encephalomyelitis induced with the aid of a substance from Bordetella pertussis. Infect Immun 21:627–637
Bernard C, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J (1998) Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75:77–88
Bettelli E (2007) Building different mouse models for human MS. Ann NY Acad Sci 1103:11–18
Blakemore WF, Franklin RJ (2008) Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol 318:193–212
Boyton RJ, Davies S, Marden C, Fantino C, Reynolds C, Portugal K, Dewchand H, Altmann DM (2005) Stat4-null non-obese diabetic mice: protection from diabetes and experimental autoimmune encephalomyelitis, but with concomitant epitope spread. Int Immunol 17(9):1157–1165
Brok HPM, Uccelli A, Kerlero de Rosbo N, Bontrop RE, Roccatogliata L, de Groot NG, Capello E, Laman HD, Nicolay K, Ben-Nun A, ’t Hart BA (2000) Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope MOG24-36 is presented by a monomorphic MHC Class II molecule. J Immunol 165:1093–1101
Brok HPM, Bauer J, Jonker M, Blezer E, Amor S, Bontrop RE, Laman JD, ’t Hart BA (2001) Non-human models of multiple sclerosis. Immunol Rev 183:173–185
Bӧ L, Vedeler C, Nyland H, Trapp B, Mӧrk S (2003a) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62:723–732
Bӧ L, Vedeler C, Nyland H, Trapp B, Mӧrk S (2003b) Intracortical cortical lesions are not associated with increased lymphocyte infiltration. Mult Scler 9:323–331
Cannon J, Collins A, Mody P, Balachandran D, Henriksen K, Smith C, Tong J, Clay B, Miller S, Sperling A (2008) CD43 regulatesTh2 differentiation and inflammation. J Immunol 180(11):7385–7393
Chard D, Miller D (2009) Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging. J Neurol Sci 282:5–11
Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo JR, Oppenheim JJ, Howard OM (2006) Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol 36(3):671–680
Confavreux C, Vukusic S (2014) The clinical course of multiple sclerosis. In: Goodin DS (ed) Handbook of clinical neurology: multiple sclerosis and related disorders, vol 122 (3rd series). Elsevier B.V., Amsterdam, pp 343–369
Constantinescu CS, Farooqi N, O’Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model of multiple sclerosis (MS). Br J Pharmacol 164:1079–1106
Correale J, Ysrraelit M, Fiol M (2012) Benign multiple sclerosis: does it exist? Curr Neurol Neurosci Rep 12:601–609
Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard C, Grewal IS, Ashkenazi A, Smyth M (2005) TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 832:511–519
Cross AH, Waubant E (2011) MS and the B cell controversy. Biochim Biophys Acta 1812:231–238
Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812:177–183
Dal Canto MC, Lipton HL (1979) Recurrent demyelination in chronic central nervous system infection produced by Theiler’s murine encephalomyelitis virus. J Neurosci 42:391–405
Del Pilar Martin M, Monson NL (2007) Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Front Biosci 12:2735–2749
Denic A, Johnson AJ, Beiber AJ, Warrington AE, Rodriguez M, Pirko I (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18(1):1–16
Ebers G (2006) Disease evolution in multiple sclerosis. J Neurol 253(Suppl 6):3–8
Ellwardt E, Zipp F (2014) Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol 262:8–17
Emerson MR, Gallagher RJ, Marquis JG, LeVine SM (2009) Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of experimental design. Comp Med 59(2):112–128
Fan H, Longacre A, Meng F, Patel V, Hsiao K, Koh JS, Levine JS (2004) Cytokine dysregulation induced by apoptotic cells is a shared characteristic of macrophages from nonobese diabetic and systemic lupus erythrematosus-prone mice. J Immunol 172(8):4834–4943
Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10(9):958–964
Filippi M, Valsania P, Rocca M (2007) Magnetic resonance imaging of grey matter damage in people with MS. Int MS J 14:12–21
Fuller K, Olson J, Howard L, Croxford J, Miller S (2004) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Med 102:339–361
Gardinier MV, Amiguet P, Linington C, Matthieu J-M (1992) Myelin oligodendrocyte glycoprotein is a member of the immunoglobulin superfamily. J Neurosci Res 33:177–187
Genain CP, Nguyen MH, Letvin NT, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96(6):2966–2974
Geurts J, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet Neurol 7:841–853
Geurts J, Bӧ L, Roosendaal S, Hazes T, Daniels R, Barkhof F, Witter I, van der Valk P (2007) Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 66:819–827
Gilmore C, Bo L, Owens T, Lowe J, Esiri M, Evangelou N (2006) Spinal cord grey matter demyelination in multiple sclerosis—a novel pattern of residual plaque morphology. Brain Pathol 16:202–208
Gold R, Hartung H-P, Toyka KV (2000) Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6:88–91
Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953–1971
Goodin D (2014) The epidemiology of multiple sclerosis: insights into disease pathogenesis. In: Goodin DS (ed) Handbook of clinical neurology: multiple sclerosis and related disorders, vol 122 (3rd series). Elsevier B.V., Amsterdam, pp 231–266
Greve B, Vijayakrishnan L, Kubal A, Sobel RA, Peterson RA, Wicker LS, Kuchroo VK (2004) The diabetes susceptibility of locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J Immunol 173(1):157–163
Haase CG, Guggenmos J, Brehm U, Andersson A, Olsson T, Reindl M, Schneiderwind JM, Zettl UK, Heindenreich F, Berger T, Wekerle H, Hohlfeld R, Linington C (2001) The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and healthy controls. J Immunol 114:220–225
Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal injury in murine oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. Implications for multiple sclerosis. Neurobiol Dis 30:172–173
Hidaka Y, Inaba Y, Matsuda K, Itoh M, Kayenama T, Nazakawa Y, Koh CS, Ichikawa M (2014) Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not the relapse. J Neurol Sci 340(1–2):117–122
Hilton AA, Slavin AJ, Hilton DJ, Bernard C (1995) Cloning and molecular characterization of human myelin oligodendrocyte glycoprotein. J Neurochem 65:309–318
Hofstetter HH, Shive CL, Forsthuber TG (2002) Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 169(1):117–125
Huitinga I, De Groot C, van der Valk P, Kamphorst W, Tilders F, Swaab D (2001) Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol 60:1208–1212
Huntington ND, Tomioka R, Clavarino C, Chow AM, Linares D, Mana P, Rossjohn J, Cavaero T, Qian F, Kalled SL, Bernard C, Reid HH (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral responses. Int Immunol 18(10):1473–1485
Ichikawa M, Koh C-S, Inoue A, Tsuyusaki J, Yamazaki M, Inaba Y, Sekiguchi Y, Itoh M, Yagita H, Komiyama A (2000) Anti IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol 102:56–66
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (2001) T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple scelerosis. Glia 36:220–234
Johansson AC, Lindqvist AK, Johannesson R, Holmdahl R (2003) Genetic heterogeneity of immune disorders in the non-obese diabetic mouse. Scand J Immunol 57:203–213
Johns TG, Kerlero de Rosbo N, Menon K, Abo S, Gonzales MF, Bernard C (1995) Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 154:5536–5541
Kamradt T, Soloway PD, Perkins DL, Gefter ML (1991) Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein. J Immunol 147(10):3296–3302
Keegan BM, Noseworthy JH (2005) Multiple sclerosis. Annu Rev Med 53:285–302
Keithley EM, Canto C, Zheng QY, Fischel-Ghodsian N, Johnson KR (2004) Age-related hearing loss and the ahl locus in mice. Hear Res 188(1–2):21–28
Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard C, Ben-Nun A (1993) Reactivity of myelin antigens in multiple sclerosis. J Clin Invest 92:2602–2607
Kerlero de Rosbo N, Mendel I, Ben-Nun A (1995) Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol 25:985–993
Kerlero de Rosbo N, Hoffmann M, Mendel I, Just I, Kaye J, Bakimer R, Flecher S, Abramsky O, Milo R, Karni A, Ben-Nun A (1997) Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 27:3059–3069
Kerlero de Rosbo N, Brok HPM, Bauer J, Kaye JH, ’t Hart B, Ben-Nun A (2000) Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyeltis induced by myelin/oligodendrocyte glycoprotein (MOG). Characterization of immunodominant MOG T- and B-cell epitopes. J Neuroimmunol 110:83–96
Kikutani H, Makino S (1992) The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 31:285–322
Kipp M, van der Star B, Vogel DYS, Puentes F, van der Valk P, Baker D, Amor S (2012) Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Scler Relat Disord 1:15–28
Komiya T, Sato K, Shioya H, Inagi Y, Hagiya H, Kozaki R, Imai M, Takada Y, Maeda T, Kurata H, Kurono M, Suzuki R, Otsuki K, Habashita H, Nakade S (2013) Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol 171(1):54–62
Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am J Pathol 157(7):267–276
Krishnamoorthy G, Holz A, Wekerle H (2007) Experimental models of spontaneous autoimmune disease in the central nervous system. J Mol Med 85:1161–1173
Kroepfl JF, Vise LR, Charron AJ, Linington C, Gardinier MV (1996) Investigation of myelin oligodendrocyte glycoprotein membrane topology. J Neurochem 67:2219–2222
Kuerten S, Angelov DN (2008) Comparing the CNS morphology and immunobiology of different EAE models in C57Bl/6 mice—a step towards understanding the complexity of multiple sclerosis. Ann Anat 190:1–15
Kuhle J, Pohl C, Mehling M, Edan G, Freedmann MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindbergh R, Kappos L, Sandbrink R (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356:371–378
Kurschus FC, Wortge S, Waisman A (2006) Modelling a complex disease: multiple sclerosis. In: Compston A, Lassmann H, McDonald I (eds) The story of multiple sclerosis: McAlpine’s multiple sclerosis. Churchill Livingston Elsevier, Amsterdam
Kutzelnigg A, Lucchinetti C, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi J, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712
Kutzelnigg A, Faber-Rod J, Bauer J, Lucchinetti C, Sorensen P, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H (2007) Widespread demyelination in the cerebellar cortex of multiple sclerosis. Brain Pathol 17:38–44
Lassmann H (2010a) What drives disease in multiple sclerosis: inflammation of neurodegeneration? Clin Exp Neuroimmunol 1:2–10
Lassmann H (2010b) Axonal and neuronal pathology in multiple sclerosis: what we have learnt from animal models. Exp Neurol 225:2–8
Lassmann H, Brück W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. TRENDS Mol Med 7(3):115–121
Lassmann H, Brück W, Lucchinetti C (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218
Lee D-H, Linker RA (2010) The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Exp Opin Ther Targets 16(5):451–462
Lees J, Golumbek P, Sim J (2008) Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 205:2633–2642
Levy H, Assaf Y, Frenkel D (2010) Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol 226:148–158
Levy-Barazany H, Barazany D, Puckett L, Blanga-Kanfi S, Bornstein-Auerbach N, Yang K, Peron JP, Weiner HL, Frenkel D (2014) Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE. Exp Neurol 255:63–70
Lin MH, Yeh LT, Chen SJ, Chiou HY, Chu CC, Yen LB, Lin KI, Chang DM, Sytwu HK (2014) T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in non-obese diabetic mice by increasing Th1 and Th17 cells. Clin Immunol 151(2):101–131
Linington C, Lassmann H (1987) The role of antibodies against myelin surface antigens in chronic EAE’. In: Crescenzi GC (ed) A multidisciplinary approach to demyelinating disease. Plenum Press, New York, pp 219–225
Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin oligodendrocyte glycoprotein. Am J Pathol 130:443–454
Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y, Lu HC, Lassmann H, Wekerle H (1993) T cells for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 23:1364–1372
Lu C, Pelech S, Zhang H, Bond J, Spach K, Noubade R, Blankenhorn EP, Teuscher C (2008) Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. J Neurosci Res 86:2624–2640
Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6):707–717
Ludwin SK (2006) The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 65(4):305–318
Makino S, Tochino Y (1978) The spontaneously non-obese diabetic mouse. Exp Anim 27:27–29
Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y (1980) Breeding of a non-obese diabetic strain of mice. Exp Anim 29:1–13
Makino S, Muraoka Y, Harada M, Kishimoto Y, Konishi T (1989) Characteristics of the NOD mouse and its relatives. In: Larkins R, Zimmet P, Chisolm D (eds) New lessons from diabetes in animals. Elsevier, Amsterdam, pp 747–750
Maron R, Hancock WW, Slavin A, Hattori M, Kuchroo V, Weiner HL (1999) Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol 11(9):1573–1580
Mars LT, Laloux V, Goude K, Desbois S, Saoudi A, Van Kaer L, Lassmann H, Herbelin A, Lehuen A, Liblau RS (2002) Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 168:6007–6011
Mars LT, Gautron A-S, Novak J, Beaudoin L, Diana J, Liblau RS, Lehuen A (2008) Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol 181:2321–2329
Marta M, Stridh P, Becanovic K, Gillett A, Ockinger J, Lorentzen JC, Jagodic M, Olsson T (2010) Multiple loci comprising immune-related genes regulate experimental neuroinflammation. Genes Immun 11(1):21–36
Marusic S, Thakker P, Pelker JW, Stedman NL, Lee KL, McKew JC, Han L, Xu X, Wolf ST, Borey AJ, Cui J, Shen MWH, Donahue F, Hassan-Zaharee M, Leach MW, Shimizu T, Clark JD (2008) Blockade of cytosolic phospholipase A2α prevents autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J Neuroimmunol 204:29–37
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11(1):107–116
Matthieu J-M, Amiguet P (1990) Myelin oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. Dev Neurosci 12:293–302
Mayo S, Quinn A (2007) Altered susceptibility to EAE in congenic NOD mice: altered processing of the encephalitogenic MOG35–55 peptide by NOR/J mice. Clin Immunol 122(1):91–100
Mayo S, Kohler W, Kumar V, Quinn A (2006) Insulin-dependent diabetes loci Idd5 and Idd9 increase sensitivity to experimental autoimmune encephalomyelitis. Clin Immunol 118(2–3):219–228
Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisakk P, Kallas K, Ellezam B, Bakshi R, Prat A, Antel JP, Weiner HL, Quintana FJ (2014) Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med 20(10):1147–1156
McCarthy D, Richards M, Miller S (2012) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol 900:381–401
McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard C (2001) Granulocyte macrophage colony-stimulating factor: a putative therapeutic target in multiple sclerosis. J Exp Med 194(7):873–881
Melcon M, Correale J, Melcon C (2014) Is it time for a new classification of multiple sclerosis? J Neurol Sci 344:171–181
Merkler D, Schmelting B, Czeh B, Fuchs E, Stadelman C, Bruck W (2006) Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II of multiple sclerosis lesions. Mult Scler 12:369–374
Mix E, Meyer-Reinecker H, Hartung H-P, Zettl U (2010) Animal models of multiple sclerosis—potentials and limitations. Prog Neurobiol 92:386–404
Munoz JJ, Sewell W (1984) Effect of pertussigen on inflammation caused by Freund adjuvant. Infect Immun 44:637–641
Namer IJ, Steibel J, Poulet P, Mauss Y, Mohr M, Chambron J (1994) The role of Mycobacterium tuberculosis in experimental autoimmune encephalomyelitis. Eur Neurol 34:224–227
Nelson ALA, Bieber AJ, Rodriguez M (2004) Contrasting murine models of MS. Int MS J 11:95–99
Noben-Trauth K, Zheng QY, Johnson KR (2003) Association of cadherin 23 with polygenic inheritance and genetic modification of sensorineural hearing loss. Nat Genet 35(1):21–23
Onuki M, Ayers M, Bernard C, Orian JM (2001) Axonal degeneration is an early feature in autoimmune-mediated demyelination in mice. Microsc Res Tech 52:731–739
Orian JM, Keating P, Downs LL, Hale MW, Jiang X, Pham H, LaFlamme AC (2014) Deletion of IL-4Rα in the BALB/C mouse is associated with altered lesion topography and susceptibility to experimental autoimmune encephalomyelitis. Autoimmun E-Pub. doi:10.3109/08916934.2014.987344
Papenfuss TL, Rogers CJ, Gienapp I, Yurrita M, McClain M, Damico N, Valo J, Song F, Whitacre CC (2004) Sex differences in experimental autoimmune encephalomyelitis in multiple mouse strains. J Neuroimmunol 150:59–69
Peterson J, Bӧ L, Mӧrk S, Chang A, Trapp B (2001) Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis neurons. Ann Neurol 50:389–400
Pham H, Ng S, Klopstein A, Ramp A, Ayers M, Orian JM (2009) The astrocytic response in early experimental autoimmune encephalomyelitis occurs across both the grey and white matter compartments. J Neuroimmunol 208:30–39
Pham H, Doerrbecker J, Ramp AA, D’Souza CS, Gorasia DG, Purcell AW, Ayers MM, Orian JM (2011) Experimental autoimmune encephalomyelitis (EAE) in C57Bl/6 mice is not associated with astrogliosis. J Neuroimmunol 232(1–2):51–62
Pham-Dinh D, Mattei M-G, Nussbaum J-L, Roussel G, Pontarotti P, Roeckel N, Mather IH, Artzt K, Fischer-Lindahl K, Dautigny A (1993) Myelin oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci USA 90:7990–7994
Pham-Dinh D, Allinquant B, Ruberg M, Della-Gaspera B, Nussbaum JL, Dautigny A (1994) Characterization and expression of the cDNA coding for the human myelin/oligodendrocyte glycoprotein. J Neurochem 63(6):2353–2356
Pham-Dinh D, Gaspera BD, Kerlero de Rosbo N, Dautigny A (1995) Structure of the human myelin oligodendrocyte glycoprotein gene and multiple alternative splice isoforms. Genomics 29:345–352
Pierson E, Simmons SB, Castelli L, Goverman JM (2012) Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 248(1):205–215
Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P (2014) Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 47:405–505
Quarles RH (2002) Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell Mol Life Sci 59(11):1851–1871
Racke M, Hu W, Lovett-Racke (2005) PTX cruiser: driving autoimmunity via TLR4. Trends Immunol 26(6):289–291
Raine C (1994) The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 386:S61–S72
Ramp AA, Hall C, Orian JM (2010) Strain-related effects of fenbendazole treatment on murine experimental autoimmune encephalomyellitis. Lab Anim 44:271–273
Rangachari M, Kuchroo VK (2013) Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 45:31–39
Ransohoff (2006) EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 27(4):167–168
Ransohoff RM (2014) Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci 15(8):1074–1077
Ransohoff RM, Haffler DA, Lucchinetti CF (2015) Multiple sclerosis—a quiet revolution. Nat Rev Neurol 11:134–142
Reifsnyder P, Li R, Silviera P, Churchill G, Serreze D, Leiter E (2005) Conditioning the genome identifies additional diabetes resistance loci in Type 1 diabetes resistant NOR/Lt mice. Genes Immun 6(6):528–538
Reindl M, Di Pauli F, Rostasy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9:455–461
Rivero VE, Riera CM, Roth GA (1999) Humoral response against myelin antigens in two strains of rats with different susceptibility to experimental allergic encephalomyelitis (EAE). Autoimmunity 29(2):129–137
Robinson AP, Harp CT, Noronha A, Miller SD (2014) The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol 122:173–189
Rocca M, Messina R, Filippi M (2013) Multiple sclerosis imaging: recent advances. J Neurol 260:929–935
Schluesener HJ, Sober RA, Linington C, Weiner HL (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139:4016–4021
Schmidt S (1999) Candidate autoantigens in multiple sclerosis. Mult Scler 5:147–160
Scolding NJ, Frith S, Linington C, Morgan BP, Campbell AK, Compston AS (1989) Myelin oligodendrocyte glycoprotein is a surface marker of oligodendrocyte maturation. J Neuroimmunol 22:169–176
Sekugichi Y, Ichikawa M, Inoue A, Itoh M, Koh C-S (2001) Brain-derived gangliosides suppress the chronic relapsing-remitting experimental autoimmune encephalomyelitis in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol 116:196–205
Serreze DV, Leiter EH (1994) Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 6:900–906
Serreze DV, Chapman HD, Varnum DS, Gerling I, Leiter EH, Shulz LD (1997) Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 158(8):3978–3986
Silveira PA, Baxter AG (2001) The NOD mouse as a model of SLE. Autoimmunity 34:53–64
Simmons SB, Liggitt D, Goverman JM (2014) Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis. J Immunol 193(2):555–563
Siram S, Steiner I (2005) Experimental autoimmune encephalomyelitis: a misleading model of MS. Ann Neurol 58:939–945
Skundric DS (2005) Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Curr Neurovascular Res 2:349–362
Slavin AJ, Johns TG, Orian JM, Bernard C (1996) Regulation of myelin oligodendrocyte glycoprotein in different species during development. Dev Neurosci 19:69–78
Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, Bernard C (1998) Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28:109–120
Smith P, Heijmans N, Ouwerling B, Breij E, Evans N, van Noort J, Plomp A, Delarasse C, ’t Hart B, Pham-Dinh D, Amor S (2005) Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi mice. Eur J Immunol 35:1311–1319
Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, Lassmann H, Linington C (1999) Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the “resistant” Brown norway rat: disease susceptibility is determined by MHC and MHC-linked effects in the B cell response. J Immunol 163:40–49
Stefferl A, Brehm U, Linington C (2000) The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm 58:123–133
Steinman L, Zamvil SS (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 26(11):565–571
Steinman L, Zamvil S (2006) How to successfully apply animal studies in experimental autoimmune encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12–21
Storch MK, Piddelsden S, Haltia M, Livanainen M, Morgan P, Lassmann H (1998a) Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 43:465–471
Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998b) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681–694
Strommes IM, Goverman JM (2006) Passive induction of experimental autoimmune encephalomyelitis. Nat Protoc 1:1952–1960
’t Hart BA, van Meurs M, Brok HPM, Massacesi L, Bauer J, Boon L, Bontrop RE, Laman JD (2000) A new primate model for multiple sclerosis in the common marmoset. Immunol Today 21(6):290–297
’t Hart BA, Vogels J, Bauer J, Brock HP, Blezer R (2004) Non-invasive measurement of brain damage in a primate model of multiple sclerosis. Trends Mol Med 10(2):85–91
’t Hart BA, Gran B, Weissert R (2013) EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med 17(3):119–125
Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune of neurodegenerative disorder? Annu Rev Neurosci 31:247–269
Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS (2000) Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol 10(3):402–418
van Engelen BG, Pavelko KD, Rodriguez M (1997) Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. Mult Scler 3(2):76–79
Vercellino M, Plano T, Votta B, Mutani R, Giordana M, Cavalla P (2005) Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 64:1101–1107
Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies and research. Lancet Neurol 13(9):936–948
Wang D, Ayers MM, Hazelwood LJ, Catmull DV, Bernard CCA, Orian JM (2005) Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 51:235–240
Yeh A, Chitnis T, Krupp L, Ness J, Chabas D, Kuntz N, Waubant E (2009) Pediatric multiple sclerosis. Nat Rev Neurol 5:621–631
Acknowledgments
The work was funded by the National Multiple Sclerosis Society and Novartis Pharmaceuticals Australia. The authors would like to thank LIMS and the Clive and Vera Ramaciotti and Rebecca L. Cooper Medical Research Foundations for equipment. CDS was supported by a post-graduate award from La Trobe University. We also thank A.A. Jimenez for permission to use Fig. 1 and A.A. Ramp for Fig. 2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Dang, P.T., Bui, Q., D’Souza, C.S., Orian, J.M. (2015). Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain. In: La Flamme, A., Orian, J. (eds) Emerging and Evolving Topics in Multiple Sclerosis Pathogenesis and Treatments. Current Topics in Behavioral Neurosciences, vol 26. Springer, Cham. https://doi.org/10.1007/7854_2015_378
Download citation
DOI: https://doi.org/10.1007/7854_2015_378
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-25541-5
Online ISBN: 978-3-319-25543-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)